Patent · US Active

Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity

US11638751B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

INSTITUT PASTEUR · FR

Inventors

Sylvain Baize · Val-de-Reuil, FR
Audrey Page · Villeurbanne, FR
Xavier CARNEC · Val-de-Reuil, FR
Mathieu Jean Simon Mateo · L'Essart Mador, FR
Stephanie REYNARD · La Mulatière, FR
Alexandra Fizet · Les Echets, FR

Key dates

Filing date	Nov 30, 2020
Grant date	May 2, 2023
Priority date	—
Expiry date	Feb 6, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/10062
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.